SGLT2 Inhibitors – The New HF Therapies on the Block

Published: 25 August 2020

  • Views:

    Views Icon 277
  • Likes:

    Heart Icon 1


Full programme


In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice. 

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

  • Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
  • Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
  • Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF


  • 5 mins - Welcome & introduction - Subodh Verma
  • 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
  • 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
  • 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
  • 10 mins - Faculty discussion (pre-recorded) - All Faculty
  • Close - Subodh Verma
  • Live Q&A and discussion - All Faculty

Series overview

Part 1

Welcome & Introductions

Part 2

A Brief History of SGLT2 Inhibitors

Part 3

What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective

Part 4

How Might Future Trials Affect How I Treat My Patients?

Part 5

Panel discussion

Faculty Biographies

Subodh Verma

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St. Michael’s Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis. 

View full profile